ArticleNature communications2016
Identification of Siglec-1 null individuals infected with HIV-1.
Article in Nature communications, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 33 citations in OpenAlex.
- Siglec-1-targeted nanobodies restrict HIV-1 transmission and infection of dendritic cells.Journal of virology · 2026Article
- LRP4 is an entry receptor for multiple encephalitic alphaviruses.Nature communications · 2026Article
- Role of myeloid cells expressing CD169/Siglec-1 in host-pathogen interactions.FEMS microbiology reviews · 2026Review
- Preclinical development of humanized monoclonal antibodies against CD169 as a broad antiviral therapeutic strategy.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2024Article
- Discovery, classification, evolution and diversity of Siglecs.Molecular aspects of medicine · 2023Review
- Role of Siglecs in viral infections: A double-edged sword interaction.Molecular aspects of medicine · 2023Review
- CD169 (Siglec-1) as a Robust Human Cell Biomarker of Toll-Like Receptor 9 Agonist Immunotherapy.Frontiers in cellular and infection microbiology · 2022Article
- Myeloid CD169/Siglec1: An immunoregulatory biomarker in viral disease.Frontiers in medicine · 2022Review
- Functions of CD169 positive macrophages in human diseases (Review).Biomedical reports · 2021Review
- Dissemination ofJournal of extracellular vesicles · 2021Article
- Article
- Interferon Alpha Favors Macrophage Infection by VisceralFrontiers in immunology · 2020Article
- Siglecs at the Host-Pathogen Interface.Advances in experimental medicine and biology · 2020Review
- When Dendritic Cells Go Viral: The Role of Siglec-1 in Host Defense and Dissemination of Enveloped Viruses.Viruses · 2019Review
- Article
- Anti-Siglec-1 antibodies block Ebola viral uptake and decrease cytoplasmic viral entry.Nature microbiology · 2019Article
- Antigen structure affects cellular routing through DC-SIGN.Proceedings of the National Academy of Sciences of the United States of America · 2019Article
- Breaking the Glyco-Code of HIV Persistence and Immunopathogenesis.Current HIV/AIDS reports · 2019Review
- Co- but not Sequential Infection of DCs Boosts Their HIV-Specific CTL-Stimulatory Capacity.Frontiers in immunology · 2019Article
- Role of Dendritic Cells in Natural Immune Control of HIV-1 Infection.Frontiers in immunology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 9 institutions in 4 countries.
Funding
Abstract
Siglec-1/CD169 is a myeloid-cell surface receptor critical for HIV-1 capture and infection of bystander target cells. To dissect the role of SIGLEC1 in natura, we scan a large population genetic database and identify a loss-of-function variant (Glu88Ter) that is found in ∼1% of healthy people. Exome analysis and direct genotyping of 4,233 HIV-1-infected individuals reveals two Glu88Ter homozygous and 97 heterozygous subjects, allowing the analysis of ex vivo and in vivo consequences of SIGLEC1 loss-of-function. Cells from these individuals are functionally null or haploinsufficient for Siglec-1 activity in HIV-1 capture and trans-infection ex vivo. However, Siglec-1 protein truncation does not have a measurable impact on HIV-1 acquisition or AIDS outcomes in vivo. This result contrasts with the known in vitro functional role of Siglec-1 in HIV-1 trans-infection. Thus, it provides evidence that the classical HIV-1 infectious routes may compensate for the lack of Siglec-1 in fuelling HIV-1 dissemination within infected individuals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.